Myeloma and Waldenström macroglobulinemia Co-Pay Funding Announced

Effective February 1, 2010, eligible myeloma and Waldenström macroglobulinemia patients will now be able to receive up to $10,000 in support to help offset the costs of prescription drug co-pays and other insurance related expenses.
Patients, caregivers and healthcare professionals may submit patient applications easily online through the established link on the Co-Pay webpage www.lls.org/copay. Applications can also be submitted on the toll-free line with a Co-Pay specialist. Eligibility will be determined by medical and financial need.
The Leukemia & Lymphoma Society's (LLS) Co-Pay Assistance Program offers assistance to patients toward:
• Cancer treament related co-pays
• Private health insurance premiums
• Private insurance co-pay obligations
• Medicare Part B, Medicare Plan D, Medicare Supplementary Health Insurance and Medicare Advantage premium or co-pay obligations

For more information on this and other LLS Co-Pay Assistance Program disease funds, please call 877-557-2672 or visit www.lls.org/copay.
• Chronic myelogenous leukemia-assistance is available up to $5,000
• Chronic lymphocytic leukemia-assistance is available up to $5,000
• Hodgkin lymphoma- assistance is available up to $5,000
• Non-Hodgkin lymphoma -assistance is available up to $5,000
• Myelodysplastic syndromes (MDS)-assistance is available up to $5,000
• Myeloma -assistance is available up to $10,000
• Waldenstrom macroglobulinemia -assistance is available up to $10,000

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap